Favezelimab/pembrolizumab formulation

{
  "id": "MLC-T-ONC-013539",
  "term": "Favezelimab/pembrolizumab formulation",
  "field": "Oncology and biomedicine",
  "definition": "A coformulation containing favezelimab, a humanized, immunoglobulin G4 (IgG4) monoclonal antibody (MAb) directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG3), and pembrolizumab, a humanized monoclonal IgG4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of the favezelimab/pembrolizumab formulation, favezelimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. Pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells LAG3, a member of the immunoglobulin superfamily (IgSF) expressed on various immune cells, negatively regulates both proliferation and activation of T cells. Its expression on TILs is associated with tumor-mediated immune suppression. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.",
  "synonyms": [
    "coformulated favezelimab plus pembrolizumab",
    "coformulated favezelimab/pembrolizumab",
    "coformulated MK-4280 plus MK-3475",
    "favezelimab/pembrolizumab formulation MK-4280A"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/favezelimab-pembrolizumab-formulation/"
}